



Interim report, 1 January – 30 June 2015

- 23 April marked the conclusion of the acquisition of the North American company Onyx Medical LLC, based in Memphis, TN, in the US. The company is a leading supplier to the Trauma & Extremities market segment in the Orthopaedics area.
- Net sales rose to SEK 244.6 M (189.8), corresponding to an increase of 21.4%* mainly due to the acquisition of Onyx Medical. Order bookings amounted to SEK 222.9 M (205.5), up 1.8%*.
- Operating profit adjusted for non-recurring expenses totalled SEK 26.8 M (17.5) up 52.2%*. This improvement was mainly attributable to the acquisition of Onyx Medical and the volume growth reported by other units. Operating profit including non-recurring expenses corresponding to SEK 5.5 M (0) totalled to SEK 21.3 M (17.5).
- Profit after net financial items totalled SEK 18.6 M (15.1). Net financial items were positively impacted by exchange-rate differences of SEK 0.3 M (0.1).
- Profit after tax totalled to SEK 13.2 M (11.2), corresponding to SEK 2.18 (1.85) per share.
- Cash flow after investments totalled a negative SEK 145.8 M (pos: 28.1), of which corporate acquisitions accounted for a negative SEK 160.4 M.
- In accordance with a resolution by the Annual General Meeting, the company changed its registered name to Elos Medtech AB during the second quarter.

* Adjusted for exchange-rate fluctuations.

President and CEO, Johannes Lind-Widestam, comments:

“We experienced favourable sales growth in the second quarter, mainly due to the acquisition of Onyx. We also reported a continued healthy sales trend in the Dental Implant Systems and Diagnostics market segments. Operating profit continued to improve in line with our expectations due to the acquisition and as a result of our continued volume growth in other units. Order bookings during the second quarter grew 32.4%. However, we observed a temporary slowdown in the Medical Devices market segment, where we expect a slightly weaker trend in the near future. There is a high level of activity with respect to the integration business relations with Onyx and we hope to see strong growth figures in the Trauma & Spine market segment in the future.”

	Apr-Jun 2015	Apr-Jun 2014	Jan-Jun 2015	Jan-Jun 2014	Jul-Jun 2014/15	Jan-Dec 2014
Order bookings, SEK M	126.8	90.1	222.9	205.5	435.5	418.1
Net sales, SEK M	139.1	101.3	244.6	189.8	435.7	380.9
Growth, %*	29.9	0.7	21.4	-1.8	18.1	0.7
EBITDA, SEK M	28.0	19.6	43.3	34.7	76.4	67.8
EBITDA, %	20.1	19.3	17.7	18.3	17.5	17.8
Operating profit, SEK M	15.6	11.1	21.3	17.5	36.9	33.1
Operating margin, %	11.2	11.0	8.7	9.2	8.5	8.7
Profit after financial items, SEK M	11.0	10.8	18.6	15.1	35.3	31.8
Profit after tax, continuing operations, SEK M	7.6	8.0	13.2	11.2	25.4	23.4
Profit after tax, discontinued operations, SEK M	-	94.0	-	97.1	-3.7	93.4
Profit after tax, total, SEK M	7.6	102.0	13.2	108.3	21.7	116.8
Profit after tax per share, continuing operations, SEK	1.25	1.32	2.18	1.85	4.20	3.87

* Adjusted for exchange-rate fluctuations.

Operations in general

Following the divestment of the Metrology business area during the second quarter of 2014, the Group's operations are totally focused on the Medical Technology business area and, as a result, are reported as a single operating segment as of 1 January 2015. Operations are conducted at facilities in Sweden, Denmark, China and the US. The company, which changed its registered name to Elos Medtech AB during the second quarter, is one of Europe's leading partners in the development and production of medical technology products and components, such as dental and orthopaedic implants and instruments. Customers consist primarily of internationally active medical technology companies in the market segments of Dental Implant Systems (formerly named Dental), Diagnostics, Medical Devices and Trauma & Spine (formerly named Orthopaedics).

Programmes aimed at future development and expansions are continuing. The aim is to strengthen the global structure and, thus, the market position in current market segments. To ensure continuing organic growth, it is crucial that efficiency-enhancement and automation programs are pursued further, and that greater efforts are made to develop quality work. There will also be a continuing focus on developing support-related services, as well as a continuing build-up of sales resources. Effective cost control is necessary in parallel with these efforts.

One stage of this expansion is growth through acquisitions that complement the existing structure, which was realised through the acquisition of the North American company Onyx Medical LLC. The acquisition was concluded in the second quarter and is included in the consolidated financial statements as of 23 April. The company is based in Memphis, TN, in the US, and is a leading supplier to the Trauma & Extremities segment in the Orthopaedic area. The company had about 120 employees and sales of approximately SEK 135 M during 2014. The acquisition has strengthened the Group's market position in the Trauma & Extremities segment and, combined with current operations, will serve as a platform for the Group's development in North America. The acquisition contributed SEK 31.5 M in sales during the second quarter. If the acquisition had been completed at the beginning of the year, the sales contribution would have been SEK 79.2 M. Earnings from the acquisition have exceeded expected levels and have contributed significantly to the Group's earnings. This is partly due to the launch activities of a number of customers. Refer to Note 1 for a preliminary description of the acquisition.

Sales

April-June 2015

Consolidated net sales during the second quarter rose to SEK 139.1 M (101.3). Adjusted for exchange-rate fluctuations, the increase was 29.9%, mainly attributable to the acquisition of Onyx Medical. Order bookings during the quarter totalled SEK 126.8 M which, adjusted for exchange-rate fluctuations, represents an increase of 32.4%, primarily due to the acquisition of Onyx Medical.

January-June 2015


Consolidated net sales for the first six months of the year rose to SEK 244.6 M (189.8). Adjusted for exchange-rate fluctuations, the increase was 21.4%, mainly attributable to the acquisition of Onyx Medical. Order bookings for the first half-year amounted to SEK 222.9 M which, adjusted for exchange-rate fluctuations, represents an increase of 1.8%. The company's accumulated order bookings were impacted positively by the acquisition of Onyx Medical and negatively by a change in order patterns combined with weaker demand in the Medical Devices segment.

The demand trend remains generally positive. Although a temporary decline was noted in the Medical Devices market segment, other market segments displayed favourable growth. The decline in Medical Devices was primarily the effect of inventory adjustments carried out by a major customer, which are also expected to result in a lower level in the third quarter. In the Diagnostics market segment, the company's major customers are performing according to plan and new business is being implemented progressively. In the Trauma & Spine market segment, the acquisition of Onyx Medical was the main contributing factor behind the company's strong performance, but other customers also developed as expected. The Dental Implant Systems market segment continued to display stable growth and a high level of activity.

The Group's strategy is to develop proprietary products that complement our customers' product range, such as various types of instruments. This product range is being developed continuously and new products have already been and will be introduced during 2015. Growth during the first six months of the year amounted to about 59%. Proprietary products accounted for about 10% (7) of consolidated net sales at 30 June 2015.

Net sales by market segment	Apr-Jun	Apr-Jun	Jan-Jun	Jan-Jun	Jul-Jun	Jan-Dec
SEK M	2015	2014	2015	2014	2014/15	2014
Dental Implant Systems	40.6	38.0	78.9	73.5	146.8	141.4
Diagnostics	7.9	3.7	14.2	8.8	24.5	19.1
Medical Devices	43.9	46.8	94.0	85.9	181.9	173.8
Trauma & Spine	46.7	12.8	57.5	21.6	82.5	46.6
Total net sales	139.1	101.3	244.6	189.8	435.7	380.9

Net sales (SEK M)



Earnings

April-June 2015

Operating profit during the second quarter was SEK 15.6 M (11.1), corresponding to an operating margin of 11.2% (11.0). Profit for the quarter was charged with non-recurring expenses of SEK 0.7 M (0) in conjunction with acquisitions, as well as twofold CEO expenses of SEK 0.3 M (0), which have now been concluded. Adjusted for these items, the operating margin was 11.9% (11.1). The underlying profit was mainly improved through the acquisition of Onyx Medical. Consolidated net financial items were adversely impacted by translation differences corresponding to an expense of SEK 2.7 M (income: 0.7) and amounted to an expense of SEK 4.6 M (expense: 0.3). Profit after financial items totalled SEK 11.0 M (10.8). Profit after tax for continuing operations totalled to SEK 7.6 M (8.0), corresponding to SEK 1.25 (1.32) per share. The Group's comprehensive income totalled SEK 0.8 M (102.6*). Comprehensive earnings per share were SEK 0.13 (16.96*).

January-June 2015

Operating profit for the first six months of the year was SEK 21.3 M (17.5), corresponding to an operating margin of 8.7% (9.2). Profit for the first half-year was charged with non-recurring expenses of SEK 4.4 M (0) in conjunction with acquisitions, as well as twofold CEO expenses of SEK 1.1 M (0), which have now been concluded. Adjusted for these items, the operating margin was 11.0% (9.2). The underlying profit was improved primarily through a positive volume trend and the acquisition of Onyx Medical. The Group's net financial items were positively affected by translation differences corresponding to SEK 0.3 M (0.1) and amounted to an expense of SEK 2.7 M (expense: 2.4). Profit after financial items totalled SEK 18.6 M (15.1). Profit after tax for continuing operations totalled to SEK 13.2 M (11.2), corresponding to SEK 2.18 (1.85) per share. The Group's comprehensive income totalled SEK 6.4 M (107.4*). Comprehensive earnings per share were to SEK 1.06 (17.75*).

* Comparable figures include profit from discontinued operations.

Earnings	Apr-Jun 2015	Apr-Jun 2014	Jan-Jun 2015	Jan-Jun 2014	Jul-Jun 2014/15	Jan-Dec 2014
EBITDA, SEK M	28.0	19.6	43.3	34.7	76.4	67.8
EBITDA, %	20.1	19.3	17.7	18.3	17.5	17.8
EBIT, SEK M	15.6	11.1	21.3	17.5	36.9	33.1
EBIT, %	11.2	11.0	8.7	9.2	8.5	8.7
Profit after financial items, SEK M	11.0	10.8	18.6	15.1	35.3	31.8
Profit after tax, continuing operations, SEK M	7.6	8.0	13.2	11.2	25.4	23.4

Investments

Group investments in buildings, land, machinery and equipment amounted to SEK 39.8 M (10.8) and primarily pertained to increased machinery capacity to meet higher demand, the initiation of the expansion of Microplast's facilities and, to a certain extent, replacement investments. In addition, SEK 1.5 M (0.6) was invested in capitalised development costs and SEK 0.6 M (1.6) in other intangible fixed assets. Furthermore, the acquisition of Onyx Medical resulted in investments of SEK 263.1 M in goodwill, other intangible assets, buildings, machinery and equipment.

Financial position and liquidity

Total consolidated assets rose during the first six months of the year and amounted to SEK 846.5 M (607.7). This increase in total assets was primarily due to the acquisition of Onyx Medical.

The Group's shareholders' equity totalled SEK 326.8 M (338.6). Shareholders' equity per share was SEK 54.01 (55.96). Risk-bearing equity at the end of the period amounted to SEK 346.4 M (359.8), corresponding to 40.9% (59.2) of total capital. The Group's equity/assets ratio was 38.6% (55.7).

The Group's cash flow from operating activities was SEK 33.1 M (34.5). Cash flow after investments and sales of fixed assets amounted to a negative SEK 145.8 M (pos: 28.1), of which corporate acquisitions accounted for a negative SEK 160.4 M.

The Group's net borrowing increased during the period to SEK 313.4 M (58.0) as a result of the acquisition of Onyx Medical.

The Group's cash and cash equivalents, including unutilised overdraft facilities, totalled SEK 83.8 M (182.7).

Personnel

At the end of the quarter, the Group had 524 full-time employees, compared with 387 at year-end.

Forecast for 2015

The conditions for stable growth during 2015 are deemed satisfactory.

Discontinued operations

The subsidiary Elos Fixturlaser, which comprised the Metrology business area, was divested as of 30 June 2014. The sale generated a capital gain of SEK 88.2 M and a cash injection of SEK 125.3 M before divestment costs for the Group. The supplementary purchase consideration, calculated at SEK 1.3 M, was settled during the first quarter of 2015.

Earnings for Elos Fixturlaser for the half-year of 2014 are included in this interim report. Earnings from the discontinued operations have been excluded from all income and cost items in the income statement and are recognised as net profit, after tax, in the item "Profit from discontinued operations".

Parent Company

In addition to central management issues, the Parent Company provides Group-wide support activities, such as market support, quality management, finance and financial control.

The Parent Company's net sales for the first six months of the year amounted to SEK 7.8 M (6.3). Profit after financial items totalled SEK 3.8 M (108.2). Profit includes intra-Group dividends of SEK 9.9 M (7.2). The Parent Company's comprehensive income amounted to SEK 4.7 M (104.0). The percentage of risk-bearing capital was 70.8% (92.8). The equity/assets ratio was 70.2% (92.4). The Parent Company's cash and cash equivalents, including unutilised overdraft facilities, amounted to SEK 34.5 M (145.4).

Significant risks and uncertainties

The Group's significant risks and uncertainties include business risks associated with customers and suppliers, and other external factors, such as risks related to the prices of input goods. Financial risks also arise in conjunction with changes in exchange and interest rates. A detailed description of the Group's risks and uncertainties, and how they are managed, is presented in the Board of Directors' Report in the 2014 Annual Report.

Related-party transactions

The company had no on-going transactions with related parties during the reporting period.

Segment reporting

Following the divestment of the Metrology business area during 2014, the Group's operations comprise a single business segment: producing, developing and selling medical technology products, components and services. Accordingly, effective 1 January 2015, the consolidated statement of comprehensive income and statement of financial position pertain in all respects to one business segment.

Accounting policies

The consolidated financial statements for 2015, similar to the year-end accounts for 2014, were prepared in accordance with International Financial Reporting Standards (IFRS), as adopted by the EU, and with the Swedish Annual Accounts Act. The Parent Company's accounts were prepared in accordance with the Annual Accounts Act and recommendation RFR 2 Reporting for Legal Entities, issued by the Swedish Financial Reporting Board.

This interim report was prepared in accordance with IAS 34. The term IFRS in this document includes application of both IAS and IFRS standards, as well as interpretations of these standards as published by the IASB's Standards Interpretation Committee (SIC) and the International Financial Reporting Interpretations Committee (IFRIC).

The Group applies the same accounting policies as those described in the 2014 Annual Report. New or revised recommendations with application from 2015 are not considered to have any significant impact on the financial statements.

Audit review

This interim report is has not been reviewed by the company's auditor.

Financial information 2015

The interim report for January–September 2015 will be published on 23 October 2015.

The year-end report for 2015 will be published on 25 February 2016.

The Annual Report for 2015 will be published in March/April 2016.

Press and analyst conference

Due to the publication of the interim report, a press and analyst conference will be held on Friday 21 August at 8:00 a.m. (CET) at Remium's premises on Kungsgatan 12-14 in Stockholm, Sweden. The report will be presented and commented in Swedish by President and CEO Johannes Lind-Widestam. Information in English will be available on Elos Medtech's website shortly after the presentation via the link

<http://elosmedtech.com/investor-relations/presentations-and-images/>. A brief interview in Swedish with Johannes Lind-Widestam will be available later during the day via the link <http://www.introduce.se/foretag/elos/> on Remium's website.

For further information, contact:

Johannes Lind-Widestam, President and CEO, +46 (0)705-41 72 22, e-mail: johannes.lind-widestam@elosmedtech.com

Ulrica Ehn, CFO, +46 (0)510-48 43 67, +46 (0)702-72 11 61, e-mail: ulrica.ehn@elosmedtech.com

The Board of Directors and President hereby provide their assurance that this interim report presents an accurate overview of the company's and Group's operations, financial position and earnings, and describes the significant risks and uncertainties facing the company and the companies included in the Group.

Elos Medtech AB (publ)
Lidköping, 21 August 2015

Stig-Arne Blom
Chairman of the Board

Agneta Bengtsson Runmarker
Board member

Jeppe Magnusson
Board member

Yvonne Mårtensson
Board member

Mats Nilsson
Board member

Thomas Öster
Board member

The information in this interim report is such that Elos Medtech AB (publ) is obligated to publish in accordance with the Securities Market Act and/or the Financial Instruments Trading Act.
The information was issued for publication on 21 August 2015, at 8:00 a.m. (CET).

**CONSOLIDATED INCOME STATEMENT
AND STATEMENT OF COMPREHENSIVE INCOME**

SEK M	Apr-Jun 2015	Apr-Jun 2014	Jan-Jun 2015	Jan-Jun 2014	Jul-Jun 2014/15	Jan-Dec 2014
INCOME STATEMENT						
Net sales	139,1	101,3	244,6	189,8	435,7	380,9
Cost of goods sold	-95,5	-71,3	-169,7	-136,8	-306,1	-273,2
Gross profit	43,6	30,0	74,9	53,0	129,6	107,7
Selling expenses	-7,5	-5,7	-13,5	-10,4	-24,2	-21,1
Administration expenses	-17,2	-10,8	-34,4	-20,7	-57,8	-44,1
Development expenses	-3,5	-2,7	-6,3	-4,9	-11,3	-9,9
Other operating income/expenses	0,2	0,3	0,6	0,5	0,6	0,5
Operating profit	15,6	11,1	21,3	17,5	36,9	33,1
Financial income	0,1	0,3	0,2	0,4	0,9	1,1
Financial expenses	-2,0	-1,3	-3,2	-2,9	-6,0	-5,7
Exchange-rate differences	-2,7	0,7	0,3	0,1	3,5	3,3
Profit after net financial items	11,0	10,8	18,6	15,1	35,3	31,8
Income taxes	-3,4	-2,8	-5,4	-3,9	-9,9	-8,4
Net profit for the year from continuing operations	7,6	8,0	13,2	11,2	25,4	23,4
Profit from discontinued operations, operations	-	2,1	-	5,2	-	5,2
Profit from discontinued operations, sales transaction	-	91,9	-	91,9	-3,7	88,2
Profit from discontinued operations, total	0,0	94,0	0,0	97,1	-3,7	93,4
Net profit after taxes	7,6	102,0	13,2	108,3	21,7	116,8
Profit attributable to:						
Parent company shareholders	7,6	102,0	13,2	108,3	21,7	116,8
STATEMENTS OF COMPREHENSIVE INCOME						
Net profit after taxes	7,6	102,0	13,2	108,3	21,7	116,8
Other comprehensive income						
Items that will not be reclassified to the income statement						
Actuarial gains and losses	-3,4	-0,8	-3,4	-0,8	-8,3	-5,7
Taxes	0,8	0,2	0,8	0,2	1,2	0,6
	-2,6	-0,6	-2,6	-0,6	-7,1	-5,1
Items that may be reclassified to the income statement						
Translation differences	-7,0	5,0	-3,4	3,8	9,7	16,9
Translation of hedging of net investments	3,3	-4,3	-0,7	-4,8	-8,7	-12,8
Taxes	-0,5	0,5	-0,1	0,7	1,3	2,1
	-4,2	1,2	-4,2	-0,3	2,3	6,2
Other comprehensive income, net	-6,8	0,6	-6,8	-0,9	-4,8	1,1
Comprehensive income for the period	0,8	102,6	6,4	107,4	16,9	117,9
Comprehensive income for the period attributable to:						
Parent company shareholders	0,8	102,6	6,4	107,4	16,9	117,9
EBITDA	20,1%	19,3%	17,7%	18,3%	17,5%	17,8%
EBIT	11,2%	11,0%	8,7%	9,2%	8,5%	8,7%
Depreciation charged against earnings, continuing operations	12,4	8,5	22,0	17,2	39,5	34,7
Earnings per share (SEK), continuing operations *	1:25	1:32	2:18	1:85	4:20	3:87
Earnings per share (SEK), discontinued operations *	-	15:53	-	16:05	-0:61	15:43
Earnings per share (SEK), total *	1:25	16:86	2:18	17:90	3:59	19:30
Number of shares (thousands) *	6 051	6 051	6 051	6 051	6 051	6 051
Number of shares end of period (thousands)	6 051	6 051	6 051	6 051	6 051	6 051

* Attributable to parent company shareholders' share of net profit after taxes. Dilution does not exist since convertibles issued 1 July 2011 did not lead to conversion at expiring date of 30 June 2014.

CONDENSED CONSOLIDATED BALANCE SHEET

SEK M	30 Jun 2015	30 Jun 2014	31 Dec 2014
Assets			
Intangible fixed assets	231,5	64,6	68,5
Tangible fixed assets	348,7	212,9	230,1
Financial fixed assets	4,4	5,2	5,9
Other current assets	226,7	233,4	177,7
Cash and bank balances	35,2	77,8	125,5
Total assets	846,5	593,9	607,7
Shareholders' equity and liabilities			
Shareholders' equity	326,8	328,1	338,6
Long-term liabilities	363,2	155,9	162,7
Current liabilities	156,5	109,9	106,4
Total shareholders' equity and liabilities	846,5	593,9	607,7

KEY FIGURES

		Jan-Jun 2015	Jan-Jun 2014 *	Jan-Dec 2014 *
Return on operating capital				
from continuing operations	%	7,7	9,7	8,2
Return on shareholders' equity	%	7,9	77,2	40,9
Share of risk-bearing capital	%	40,9	59,4	59,2
Equity/assets ratio	%	38,6	55,3	55,7
Net debt	SEK M	313,4	94,4	58,0
Investments continuing operations				
excluding acquisition	SEK M	41,9	13,0	41,0
Number of employees				
in continuing operations		455	378	378
Shareholders' equity per share	SEK	54:02	54:23	55:96
Dividends	SEK	-	-	3:00

* Comparative figures are unchanged from previous reports where otherwise indicated.

CHANGES IN SHAREHOLDERS' EQUITY

SEK M	30 Jun 2015	31 Dec 2014
Opening balance	338,6	232,8
Dividends	-18,2	-12,1
Comprehensive income for the period	6,4	117,9
Closing balance, shareholders' equity	326,8	338,6

CONSOLIDATED CASH FLOW STATEMENT

SEK M	Apr-Jun 2015	Apr-Jun 2014	Jan-Jun 2015	Jan-Jun 2014	Jul-Jun 2014/15	Jan-Dec 2014
Profit after net financial items	11,0	10,8	18,6	15,1	35,3	31,8
Reversal of depreciation	12,3	8,5	21,9	17,2	39,4	34,7
Adjustment items	4,7	6,6	5,9	6,6	5,1	5,8
Income tax paid	-5,7	-2,8	-10,0	-4,4	-16,4	-10,8
Change in working capital	-1,3	4,3	-3,3	0,0	-9,5	-6,2
Cash flow from operations	21,0	27,4	33,1	34,5	53,9	55,3
Investments in fixed assets	-12,6	-2,4	-18,6	-6,4	-36,1	-23,9
Acquisition of company	-160,4	-	-160,4	-	-160,4	-
Sales of fixed assets	0,0	-	0,1	-	0,3	0,2
Balance after investments in fixed assets	-152,0	25,0	-145,8	28,1	-142,3	31,6
Change of bank overdraft facility	0,5	-13,4	6,9	-10,1	5,6	-11,4
New long-term loans	83,4	1,3	85,6	12,6	93,5	20,5
Amortization of long-term loans	-5,6	-19,1	-17,0	-24,2	-34,1	-41,3
Realized financial exchange-rate differences	-2,8	-1,3	-2,8	-1,3	-10,3	-8,8
Dividends	-18,2	-12,1	-18,2	-12,1	-18,2	-12,1
Cash flow for the period from continuing operations	-94,7	-19,6	-91,3	-7,0	-105,8	-21,5
Cash flow from discontinued operations	-	70,8	-	60,3	59,8	120,1
Cash flow for the period	-94,7	51,2	-91,3	53,3	-46,0	98,6
Liquid funds at beginning of the year	130,8	28,2	125,5	31,2	77,8	31,2
Liquid funds in discontinued operations	-	-2,0	-	-6,8	-	-6,8
Exchanges-rate differences in liquid funds	-0,9	0,4	1,0	0,1	3,4	2,5
Liquid funds at end of the period	35,2	77,8	35,2	77,8	35,2	125,5

QUARTERLY FIGURES - GROUP CONTINUING OPERATIONS

SEK M	Q 2 2015	Q 1 2015	Q 4 2014	Q 3 2014	Q 2 2014	Q 1 2014	Q 4 2013	Q 3 2013	Q 2 2013	Q 1 2013
Net sales	139,1	105,5	106,2	84,9	101,3	88,5	96,5	82,7	98,2	90,7
Cost of goods sold	-95,5	-74,2	-75,8	-60,6	-71,3	-65,5	-69,5	-62,7	-73,2	-67,4
Gross profit	43,6	31,3	30,4	24,3	30,0	23,0	27,0	20,0	25,0	23,3
Selling, adm. and developm.exp.	-28,2	-26,0	-21,7	-17,4	-19,2	-16,8	-18,2	-15,4	-18,3	-16,5
Other operating items	0,2	0,4	-0,1	0,1	0,3	0,2	0,6	-1,2	0,8	0,1
Operating profit	15,6	5,7	8,6	7,0	11,1	6,4	9,4	3,4	7,5	6,9
Net financial items	-1,9	-1,0	-1,0	-1,1	-1,0	-1,5	-1,5	-1,4	-1,6	-1,7
Exchange-rate differences	-2,7	2,9	1,4	1,8	0,7	-0,6	0,4	-1,3	1,5	-0,2
Profit after net financial items	11,0	7,6	9,0	7,7	10,8	4,3	8,3	0,7	7,4	5,0
Income taxes	-3,4	-2,0	-4,4	-0,1	-2,8	-1,1	-2,0	-0,1	-0,9	-1,5
Net profit after taxes continuing operations	7,6	5,6	4,6	7,6	8,0	3,2	6,3	0,6	6,5	3,5

**PARENT COMPANY INCOME STATEMENT AND
STATEMENTS OF COMPREHENSIVE INCOME**

SEK M	Apr-Jun 2015	Apr-Jun 2014	Jan-Jun 2015	Jan-Jun 2014	Jul-Jun 2014/15	Jan-Dec 2014
INCOME STATEMENT						
Net sales	4,1	2,9	7,8	6,3	12,6	11,1
Cost of goods sold	-	-	-	-	-	-
Gross profit	4,1	2,9	7,8	6,3	12,6	11,1
Selling expenses	-2,0	-1,3	-3,7	-2,0	-5,3	-3,6
Administration expenses	-4,7	-3,6	-9,7	-7,3	-17,2	-14,8
Other operating income/expenses	-0,1	0,0	-0,1	0,0	-0,2	-0,1
Operating profit	-2,7	-2,0	-5,7	-3,0	-10,1	-7,4
Result from participations in group comp.	0,0	7,2	9,9	7,2	21,2	18,5
Result from the sell of shares in group comp.	-	103,9	-	103,9	-5,6	98,3
Financial income	1,3	0,4	1,5	0,6	2,4	1,5
Financial expenses	-0,5	-	-0,5	-0,5	-0,7	-0,7
Exchange-rate differences	-1,3	-0,3	-1,4	0,0	-1,4	0,0
Profit after net financial items	-3,2	109,2	3,8	108,2	5,8	110,2
Appropriations	-	-	-	-	-0,5	-0,5
Income taxes	0,8	-0,4	1,4	-0,2	0,4	-1,2
Net profit/loss after taxes	-2,4	108,8	5,2	108,0	5,7	108,5

STATEMENTS OF COMPREHENSIVE INCOME

Net profit/loss after taxes	-2,4	108,8	5,2	108,0	5,7	108,5
Other comprehensive income						
Items that may be reclassified to the income statement						
Translation of hedging of net investments	3,3	-4,3	-0,7	-4,8	-8,7	-12,8
Tax	-0,7	0,7	0,2	0,8	2,2	2,8
Other comprehensive income, net	2,6	-3,6	-0,5	-4,0	-6,5	-10,0
Comprehensive income for the period	0,2	105,2	4,7	104,0	-0,8	98,5

CONDENSED PARENT COMPANY BALANCE SHEET

SEK M	30 Jun 2015	30 Jun 2014	31 Dec 2014
Assets			
Intangible fixed assets	4,1	5,7	4,9
Tangible fixed assets	0,1	0,2	0,1
Financial fixed assets	342,0	171,7	173,2
Other current assets	20,2	71,5	10,0
Cash and bank balances	0,9	65,1	105,4
Total assets	367,3	314,2	293,6
Shareholders' equity and liabilities			
Shareholders' equity	253,8	272,8	267,3
Untaxed reserves	5,2	4,7	5,2
Provisions	4,5	4,6	4,5
Long-term liabilities	65,9	1,7	0,9
Current liabilities	37,9	30,4	15,7
Total shareholders' equity and liabilities	367,3	314,2	293,6

Note 1 Acquisition analysis (preliminary)

Currency rate at time of acquisition has been used

Acquisition of Onyx Medical LLC

Description of the acquisition

23 April 2015 marked the completion of the acquisition of Onyx Medical LLC by Elos Medtech U.S Holdings Inc., a newly established subsidiary of Elos AB. As of 23 April 2015, controlling influence was attained and, thus, the company is included in the Elos consolidated financial statements. The acquisition is reported in line with the purchase method, whereby the entire purchase consideration is allocated among acquired assets and assumed liabilities. These assets and liabilities are determined at fair value pursuant to the application of generally accepted principles.

The consideration after deduction of the net loan debt amounted to SEK 164.9 M, plus a contingent consideration based on the business trend in 2015 and 2016, estimated to amount to SEK 77.2 M. The amount of the contingent consideration is limited. The consideration has been financed through liquid assets and loan.

Transaction costs for the acquisition are estimated at SEK 6.4 M, of which SEK 2.0 M was included in operating costs for the fourth quarter of 2014, SEK 4.4 M is included in operating costs for the first half-year of 2015. The transaction costs are recognised in the item "Administration costs" in the consolidated income statement.

For the period after the acquisition date and for the remainder of the year, the acquisition is expected to contribute sales of approximately SEK 110 M and will, after consolidated depreciation/amortisation and interest, have a significant positive effect on earnings per share during 2015. This positive impact is expected to continue into 2016 and subsequent years. The acquisition contributed SEK 31.5 M in sales during the second quarter. If the acquisition had been completed at the beginning of the year, the sales contribution would have been SEK 79.2 M. Earnings from the acquisition have exceeded expected levels and have contributed significantly to the Group's earnings. This is partly due to the launch activities of a number of customers.

Description of the company

Onyx Medical LLC is based in Memphis, TN, US, and is a leading supplier to the Trauma and Extremities segment in the orthopaedic area. The company has some 120 employees and reported sales of approximately SEK 135 M in 2014. The previous management will continue to lead the company after the acquisition, and will also be part of Elos' management organisation. The company's customers consist of global medical technology companies. The company has a production facility of about 5,400 square metres, fitted modern equipment and automated production processes, and can manage future expansion. Operations are certified in line with the requirements imposed by the medical technology market.

The acquisition strengthens Elos' market position in the Trauma & Extremities segment and, combined with existing operations, will function as a platform for the Group's development in North America. Following the acquisition, Elos now has a presence in Asia, Europe and North America and, with its current operations, will be better positioned with increasing potential to serve the global market.

Acquisition value, goodwill and cash-flow effects (preliminary)

Acquisition value, SEK M

Purchase consideration	
- consideration paid in cash	164,9
- estimated contingent consideration	77,2
Total consideration	242,1
Total fair value of acquired assets and liabilities	-82,6
Goodwill	159,5

Goodwill that arose in conjunction with the acquisition consists mainly of strategic benefits and synergies, which are primarily expected to be attained within markets, sales and quality. According to US tax regulations, goodwill is deductible for tax purposes over a period of 15 years.

Net assets, SEK M	Balance sheet on the acquisition date	Adjustment to fair value	Fair value
Intangible assets	-	12,5	12,5
Fxed assets	93,2	9,5	102,7
Inventories	11,9	11,1	23,0
Receivables	14,8	-	14,8
Cash and cash equivalents	4,5	-	4,5
Interest-bearing liabilities	-65,7	-	-65,7
Other liabilities	-9,2	-	-9,2
Total acquired net assets	49,5	33,1	82,6

Cash-flow effects, SEK M

Purchase consideration paid in cash	-164,9
Cash and cash equivalents in acquired subsidiary	4,5
Effect on the Group's cash and cash equivalents	-160,4